behavioral pattern monitor
Recently Published Documents


TOTAL DOCUMENTS

8
(FIVE YEARS 0)

H-INDEX

6
(FIVE YEARS 0)

2019 ◽  
Vol 178 ◽  
pp. 42-50 ◽  
Author(s):  
Molly A. Kwiatkowski ◽  
Gerhard Hellemann ◽  
Catherine A. Sugar ◽  
Zackary A. Cope ◽  
Arpi Minassian ◽  
...  

2017 ◽  
Vol 31 (10) ◽  
pp. 1334-1346 ◽  
Author(s):  
Morgane Milienne-Petiot ◽  
Lucianne Groenink ◽  
Arpi Minassian ◽  
Jared W Young

Background: Patients with bipolar disorder mania exhibit poor cognition, impulsivity, risk-taking, and goal-directed activity that negatively impact their quality of life. To date, existing treatments for bipolar disorder do not adequately remediate cognitive dysfunction. Reducing dopamine transporter expression recreates many bipolar disorder mania-relevant behaviors (i.e. hyperactivity and risk-taking). The current study investigated whether dopamine D1-family receptor blockade would attenuate the risk-taking, hypermotivation, and hyperactivity of dopamine transporter knockdown mice. Methods: Dopamine transporter knockdown and wild-type littermate mice were tested in mouse versions of the Iowa Gambling Task (risk-taking), Progressive Ratio Breakpoint Test (effortful motivation), and Behavioral Pattern Monitor (activity). Prior to testing, the mice were treated with the dopamine D1-family receptor antagonist SCH 23390 hydrochloride (0.03, 0.1, or 0.3 mg/kg), or vehicle. Results: Dopamine transporter knockdown mice exhibited hyperactivity and hyperexploration, hypermotivation, and risk-taking preference compared with wild-type littermates. SCH 23390 hydrochloride treatment decreased premature responding in dopamine transporter knockdown mice and attenuated their hypermotivation. SCH 23390 hydrochloride flattened the safe/risk preference, while reducing activity and exploratory levels of both genotypes similarly. Conclusions: Dopamine transporter knockdown mice exhibited mania-relevant behavior compared to wild-type mice. Systemic dopamine D1-family receptor antagonism attenuated these behaviors in dopamine transporter knockdown, but not all effects were specific to only the knockdown mice. The normalization of behavior via blockade of dopamine D1-family receptors supports the hypothesis that D1 and/or D5 receptors could contribute to the mania-relevant behaviors of dopamine transporter knockdown mice.


2016 ◽  
Vol 240 ◽  
pp. 278-283 ◽  
Author(s):  
William Perry ◽  
Meghan McIlwain ◽  
Karen Kloezeman ◽  
Brook L. Henry ◽  
Arpi Minassian

2013 ◽  
Vol 150 (3) ◽  
pp. 948-954 ◽  
Author(s):  
Brook L. Henry ◽  
Arpi Minassian ◽  
Virginie M. Patt ◽  
Jessica Hua ◽  
Jared W. Young ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e24185 ◽  
Author(s):  
Arpi Minassian ◽  
Brook L. Henry ◽  
Jared W. Young ◽  
Virginia Masten ◽  
Mark A. Geyer ◽  
...  

2010 ◽  
Vol 25 (11) ◽  
pp. 1548-1561 ◽  
Author(s):  
Adam L Halberstadt ◽  
Liselore Koedood ◽  
Susan B Powell ◽  
Mark A Geyer

Psilocin (4-hydroxy- N, N-dimethyltryptamine) is a hallucinogen that acts as an agonist at 5-HT1A, 5-HT2A, and 5-HT2C receptors. Psilocin is the active metabolite of psilocybin, a hallucinogen that is currently being investigated clinically as a potential therapeutic agent. In the present investigation, we used a combination of genetic and pharmacological approaches to identify the serotonin (5-HT) receptor subtypes responsible for mediating the effects of psilocin on head twitch response (HTR) and the behavioral pattern monitor (BPM) in C57BL/6J mice. We also compared the effects of psilocin with those of the putative 5-HT2C receptor-selective agonist 1-methylpsilocin and the hallucinogen and non-selective serotonin receptor agonist 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT). Psilocin, 1-methylpsilocin, and 5-MeO-DMT induced the HTR, effects that were absent in mice lacking the 5-HT2A receptor gene. When tested in the BPM, psilocin decreased locomotor activity, holepoking, and time spent in the center of the chamber, effects that were blocked by the selective 5-HT1A antagonist WAY-100635 but were not altered by the selective 5-HT2C antagonist SB 242,084 or by 5-HT2A receptor gene deletion. 5-MeO-DMT produced similar effects when tested in the BPM, and the action of 5-MeO-DMT was significantly attenuated by WAY-100635. Psilocin and 5-MeO-DMT also decreased the linearity of locomotor paths, effects that were mediated by 5-HT2C and 5-HT1A receptors, respectively. In contrast to psilocin and 5-MeO-DMT, 1-methylpsilocin (0.6–9.6 mg/kg) was completely inactive in the BPM. These findings confirm that psilocin acts as an agonist at 5-HT1A, 5-HT2A, and 5-HT2C receptors in mice, whereas the behavioral effects of 1-methylpsilocin indicate that this compound is acting at 5-HT2A sites but is inactive at the 5-HT1A receptor. The fact that 1-methylpsilocin displays greater pharmacological selectivity than psilocin indicates that 1-methylpsilocin represents a potentially useful alternative to psilocybin for development as a potential therapeutic agent.


2007 ◽  
Vol 31 (6) ◽  
pp. 882-896 ◽  
Author(s):  
Jared W. Young ◽  
Arpi Minassian ◽  
Martin P. Paulus ◽  
Mark A. Geyer ◽  
William Perry

Sign in / Sign up

Export Citation Format

Share Document